Adjunctive immunotherapeutic agents in patients with sepsis and septic shock: a multidisciplinary consensus of 23.
Adjunctive therapies
Blood purification
Checkpoint immune therapies
Corticosteroids
Immunoglobulins
Sepsis
Septic shock
Specific immune therapies
Journal
Journal of anesthesia, analgesia and critical care
ISSN: 2731-3786
Titre abrégé: J Anesth Analg Crit Care
Pays: England
ID NLM: 9918591885906676
Informations de publication
Date de publication:
30 Apr 2024
30 Apr 2024
Historique:
received:
28
01
2024
accepted:
18
04
2024
medline:
1
5
2024
pubmed:
1
5
2024
entrez:
30
4
2024
Statut:
epublish
Résumé
In the last decades, several adjunctive treatments have been proposed to reduce mortality in septic shock patients. Unfortunately, mortality due to sepsis and septic shock remains elevated and NO trials evaluating adjunctive therapies were able to demonstrate any clear benefit. In light of the lack of evidence and conflicting results from previous studies, in this multidisciplinary consensus, the authors considered the rational, recent investigations and potential clinical benefits of targeted adjunctive therapies. A panel of multidisciplinary experts defined clinical phenotypes, treatments and outcomes of greater interest in the field of adjunctive therapies for sepsis and septic shock. After an extensive systematic literature review, the appropriateness of each treatment for each clinical phenotype was determined using the modified RAND/UCLA appropriateness method. The consensus identified two distinct clinical phenotypes: patients with overwhelming shock and patients with immune paralysis. Six different adjunctive treatments were considered the most frequently used and promising: (i) corticosteroids, (ii) blood purification, (iii) immunoglobulins, (iv) granulocyte/monocyte colony-stimulating factor and (v) specific immune therapy (i.e. interferon-gamma, IL7 and AntiPD1). Agreement was achieved in 70% of the 25 clinical questions. Although clinical evidence is lacking, adjunctive therapies are often employed in the treatment of sepsis. To address this gap in knowledge, a panel of national experts has provided a structured consensus on the appropriate use of these treatments in clinical practice.
Sections du résumé
BACKGROUND
BACKGROUND
In the last decades, several adjunctive treatments have been proposed to reduce mortality in septic shock patients. Unfortunately, mortality due to sepsis and septic shock remains elevated and NO trials evaluating adjunctive therapies were able to demonstrate any clear benefit. In light of the lack of evidence and conflicting results from previous studies, in this multidisciplinary consensus, the authors considered the rational, recent investigations and potential clinical benefits of targeted adjunctive therapies.
METHODS
METHODS
A panel of multidisciplinary experts defined clinical phenotypes, treatments and outcomes of greater interest in the field of adjunctive therapies for sepsis and septic shock. After an extensive systematic literature review, the appropriateness of each treatment for each clinical phenotype was determined using the modified RAND/UCLA appropriateness method.
RESULTS
RESULTS
The consensus identified two distinct clinical phenotypes: patients with overwhelming shock and patients with immune paralysis. Six different adjunctive treatments were considered the most frequently used and promising: (i) corticosteroids, (ii) blood purification, (iii) immunoglobulins, (iv) granulocyte/monocyte colony-stimulating factor and (v) specific immune therapy (i.e. interferon-gamma, IL7 and AntiPD1). Agreement was achieved in 70% of the 25 clinical questions.
CONCLUSIONS
CONCLUSIONS
Although clinical evidence is lacking, adjunctive therapies are often employed in the treatment of sepsis. To address this gap in knowledge, a panel of national experts has provided a structured consensus on the appropriate use of these treatments in clinical practice.
Identifiants
pubmed: 38689337
doi: 10.1186/s44158-024-00165-3
pii: 10.1186/s44158-024-00165-3
doi:
Types de publication
Journal Article
Langues
eng
Pagination
28Informations de copyright
© 2024. The Author(s).
Références
Vincent J-L et al (2006) Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34:344–353
pubmed: 16424713
doi: 10.1097/01.CCM.0000194725.48928.3A
Sakr Y et al (2013) Epidemiology and outcome of sepsis syndromes in Italian ICUs: a muticentre, observational cohort study in the region of Piedmont. Minerva Anestesiol 79:993–1002
pubmed: 23811620
Shankar-Hari M et al (2015) Judging quality of current septic shock definitions and criteria. Crit Care 19:445
pubmed: 26702879
pmcid: 4699344
doi: 10.1186/s13054-015-1164-6
Evans L et al (2021) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med 47:1181–1247
pubmed: 34599691
pmcid: 8486643
doi: 10.1007/s00134-021-06506-y
Jl V et al (2021) Equilibrating SSC guidelines with individualized care. Crit Care Lond Engl. 25(1):397
doi: 10.1186/s13054-021-03813-0
Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, Lazaro P, et al. The RAND/UCLA Appropriateness Method User's Manual. Santa Monica: RAND Corporation; 2001. https://www.rand.org/pubs/monograph_reports/MR1269.html .
Chong DLW, Sriskandan S (2011) Pro-inflammatory mechanisms in sepsis. Contrib Microbiol 17:86–107
pubmed: 21659748
doi: 10.1159/000324022
Girardin E, Grau GE, Dayer JM, Roux-Lombard P, Lambert PH (1988) Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 319:397–400
pubmed: 3135497
doi: 10.1056/NEJM198808183190703
Hotchkiss RS et al (2016) Sepsis and septic shock. Nat Rev Dis Primer 2:1–21
doi: 10.1038/nrdp.2016.45
Riewald M, Ruf W (2003) Science review: Role of coagulation protease cascades in sepsis. Crit Care 7:123–129
pubmed: 12720558
doi: 10.1186/cc1825
Bosmann M, Ward PA (2013) The inflammatory response in sepsis. Trends Immunol 34:129–136
pubmed: 23036432
doi: 10.1016/j.it.2012.09.004
Sato R, Nasu M (2015) A review of sepsis-induced cardiomyopathy. J Intensive Care 3:48
pubmed: 26566443
pmcid: 4642671
doi: 10.1186/s40560-015-0112-5
Hotchkiss RS, Monneret G, Payen D (2013) Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 13:260–268
pubmed: 23427891
pmcid: 3798159
doi: 10.1016/S1473-3099(13)70001-X
Cohen J (2002) The immunopathogenesis of sepsis. Nature 420:885–891
pubmed: 12490963
doi: 10.1038/nature01326
Torgersen C et al (2009) Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis. Anesth Analg 108:1841–1847
pubmed: 19448210
doi: 10.1213/ane.0b013e318195e11d
Ong DSY et al (2017) Epidemiology of Multiple Herpes Viremia in Previously Immunocompetent Patients With Septic Shock. Clin Infect Dis Off Publ Infect Dis Soc Am 64:1204–1210
doi: 10.1093/cid/cix120
Kethireddy S, Kumar A (2012) Mortality due to septic shock following early, appropriate antibiotic therapy: can we do better?*. Crit Care Med 40:2228–2229
pubmed: 22710207
doi: 10.1097/CCM.0b013e318256bb99
Otto GP et al (2011) The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care Lond Engl 15:R183
doi: 10.1186/cc10332
Daviaud F et al (2015) Timing and causes of death in septic shock. Ann Intensive Care 5:16
pubmed: 26092499
pmcid: 4474967
doi: 10.1186/s13613-015-0058-8
Textoris J, Mallet F (2017) Immunosuppression and herpes viral reactivation in intensive care unit patients: one size does not fit all. Crit Care Lond Engl 21:230
doi: 10.1186/s13054-017-1803-1
Hotchkiss RS, Monneret G, Payen D (2013) Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13:862–874
pubmed: 24232462
pmcid: 4077177
doi: 10.1038/nri3552
Patel GP, Balk RA (2012) Systemic steroids in severe sepsis and septic shock. Am J Respir Crit Care Med 185:133–139
pubmed: 21680949
doi: 10.1164/rccm.201011-1897CI
Arafah BM (2006) Hypothalamic pituitary adrenal function during critical illness: limitations of current assessment methods. J Clin Endocrinol Metab 91:3725–3745
pubmed: 16882746
doi: 10.1210/jc.2006-0674
Minneci PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C (2004) Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 141:47–56
pubmed: 15238370
doi: 10.7326/0003-4819-141-1-200407060-00014
Volbeda M et al (2015) Glucocorticosteroids for sepsis: systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 41:1220–1234
pubmed: 26100123
pmcid: 4483251
doi: 10.1007/s00134-015-3899-6
Annane D et al (2015) Corticosteroids for treating sepsis. Cochrane Database Syst. Rev 2015(12):CD002243
pubmed: 26633262
pmcid: 6494587
Oppert M et al (2005) Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med 33:2457–2464
pubmed: 16276166
doi: 10.1097/01.CCM.0000186370.78639.23
de Kruif MD et al (2007) Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia. J Immunol Baltim Md 1950(178):1845–1851
Gibbison B et al (2017) Corticosteroids in septic shock: a systematic review and network meta-analysis. Crit Care Lond Engl 21:78
doi: 10.1186/s13054-017-1659-4
Russell JA et al (2009) Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock*: Crit. Care Med 37:811–818
doi: 10.1097/CCM.0b013e3181961ace
Venkatesh B et al (2018) Adjunctive Glucocorticoid Therapy in Patients with Septic Shock. N Engl J Med 378:797–808
pubmed: 29347874
doi: 10.1056/NEJMoa1705835
Annane D et al (2018) Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. N Engl J Med 378:809–818
pubmed: 29490185
doi: 10.1056/NEJMoa1705716
Fine MJ et al (1996) Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis JAMA 275:134–141
pubmed: 8531309
Meijvis SCA et al (2011) Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet Lond Engl 377:2023–2030
doi: 10.1016/S0140-6736(11)60607-7
Nafae R, Ragab M, Amany F, Rashed S (2013) Adjuvant role of corticosteroids in the treatment of community-acquired pneumonia. Egypt J Chest Dis Tuberc 62:439–445
doi: 10.1016/j.ejcdt.2013.03.009
Sabry NA, Omar EE-D (2011) Corticosteroids and ICU Course of Community Acquired Pneumonia in Egyptian Settings. Pharmacol Amp Pharm 2:73–81
doi: 10.4236/pp.2011.22009
Confalonieri M et al (2005) Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 171:242–248
pubmed: 15557131
doi: 10.1164/rccm.200406-808OC
Torres A et al (2015) Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 313:677–686
pubmed: 25688779
doi: 10.1001/jama.2015.88
Blum CA et al (2015) Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Lond Engl 385:1511–1518
doi: 10.1016/S0140-6736(14)62447-8
Meduri GU et al (2022) Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. Intensive Care Med 48:1009–1023
pubmed: 35723686
pmcid: 9208259
doi: 10.1007/s00134-022-06684-3
Dequin P-F et al (2023) Hydrocortisone in Severe Community-Acquired Pneumonia. N Engl J Med 388:1931–1941
pubmed: 36942789
doi: 10.1056/NEJMoa2215145
Martin-Loeches, I. et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med. 1–18 (2023) doi: https://doi.org/10.1007/s00134-023-07033-8 .
Pitre T et al (2023) Corticosteroids in Community-Acquired Bacterial Pneumonia: a Systematic Review, Pairwise and Dose-Response Meta-Analysis. J Gen Intern Med 38:2593–2606
pubmed: 37076606
pmcid: 10115386
doi: 10.1007/s11606-023-08203-6
Ni Y-N, Chen G, Sun J, Liang B-M, Liang Z-A (2019) The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care Lond Engl 23:99
doi: 10.1186/s13054-019-2395-8
An Updated Cochrane Systematic Review and Meta-analysis, Lansbury L.E, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Shen Lim W (2020) Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis. Crit. Care Med. 48:e98–e106
doi: 10.1097/CCM.0000000000004093
van de Beek D, de Gans J (2006) Dexamethasone in adults with community-acquired bacterial meningitis. Drugs 66:415–427
pubmed: 16597160
doi: 10.2165/00003495-200666040-00002
de Gans J, van de Beek D, European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators (2002) Dexamethasone in adults with bacterial meningitis. N. Engl. J. Med 347:1549–1556
pubmed: 12432041
doi: 10.1056/NEJMoa021334
Brouwer M.C, van de Beek D (2023) Adjunctive dexamethasone treatment in adults with listeria monocytogenes meningitis: a prospective nationwide cohort study. eClinicalMedicine 58:101922
pubmed: 37007737
pmcid: 10050789
doi: 10.1016/j.eclinm.2023.101922
Täuber MG, Khayam-Bashi H, Sande MA (1985) Effects of ampicillin and corticosteroids on brain water content, cerebrospinal fluid pressure, and cerebrospinal fluid lactate levels in experimental pneumococcal meningitis. J Infect Dis 151:528–534
pubmed: 3973406
doi: 10.1093/infdis/151.3.528
Brouwer M.C, McIntyre P, Prasad K, van de Beek D (2015) Corticosteroids for acute bacterial meningitis. Cochrane Database Syst. Rev 2015(9):CD004405
pubmed: 26362566
pmcid: 6491272
Rhodes A et al (2017) Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med 45:486–552
pubmed: 28098591
doi: 10.1097/CCM.0000000000002255
Honoré PM et al (2012) New insights regarding rationale, therapeutic target and dose of hemofiltration and hybrid therapies in septic acute kidney injury. Blood Purif 33:44–51
pubmed: 22179226
doi: 10.1159/000333837
Di Carlo JV, Alexander SR (2005) Hemofiltration for cytokine-driven illnesses: the mediator delivery hypothesis. Int J Artif Organs 28:777–786
pubmed: 16211527
doi: 10.1177/039139880502800803
Lee PA, Matson JR, Pryor RW, Hinshaw LB (1993) Continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med 21:914–924
pubmed: 8504662
doi: 10.1097/00003246-199306000-00022
Ullrich R et al (2001) Continuous venovenous hemofiltration improves arterial oxygenation in endotoxin-induced lung injury in pigs. Anesthesiology 95:428–436
pubmed: 11506117
doi: 10.1097/00000542-200108000-00027
Ronco C et al (2000) Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet Lond Engl 356:26–30
doi: 10.1016/S0140-6736(00)02430-2
Cole L et al (2001) High-volume haemofiltration in human septic shock. Intensive Care Med 27:978–986
pubmed: 11497156
doi: 10.1007/s001340100963
Joannes-Boyau O et al (2013) High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med 39:1535–1546
pubmed: 23740278
doi: 10.1007/s00134-013-2967-z
Zhang P et al (2012) Effect of the intensity of continuous renal replacement therapy in patients with sepsis and acute kidney injury: a single-center randomized clinical trial. Nephrol Dial Transplant. 27(3):967–973
pubmed: 21891773
doi: 10.1093/ndt/gfr486
Clark E et al (2014) High-volume hemofiltration for septic acute kidney injury: a systematic review and meta-analysis. Crit Care Lond Engl 18:R7
doi: 10.1186/cc13184
Borthwick E.M et al (2017) High-volume haemofiltration for sepsis in adults. Cochrane Database Syst. Rev 1(1):CD008075
pubmed: 28141912
Kellum JA, Song M, Venkataraman R (2004) Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med 32:801–805
pubmed: 15090965
doi: 10.1097/01.CCM.0000114997.39857.69
Peng Z-Y, Carter MJ, Kellum JA (2008) Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Crit Care Med 36:1573–1577
pubmed: 18434884
pmcid: 3547590
doi: 10.1097/CCM.0b013e318170b9a7
Kogelmann K, Jarczak D, Scheller M, Drüner M (2017) Hemoadsorption by CytoSorb in septic patients: a case series. Crit Care Lond Engl 21:74
doi: 10.1186/s13054-017-1662-9
Schädler D et al (2017) The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trial. PLoS ONE 12:e0187015
pubmed: 29084247
pmcid: 5662220
doi: 10.1371/journal.pone.0187015
Friesecke S et al (2019) International registry on the use of the CytoSorb® adsorber in ICU patients : Study protocol and preliminary results. Med Klin Intensivmed Notfallmedizin 114:699–707
doi: 10.1007/s00063-017-0342-5
Friesecke S, Stecher S-S, Gross S, Felix SB, Nierhaus A (2017) Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study. J. Artif. Organs. 20(3):252–259
pubmed: 28589286
doi: 10.1007/s10047-017-0967-4
Cruz DN et al (2009) Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301:2445–2452
pubmed: 19531784
doi: 10.1001/jama.2009.856
Payen DM et al (2015) Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med 41:975–984
pubmed: 25862039
pmcid: 4477725
doi: 10.1007/s00134-015-3751-z
Saito N et al (2017) Efficacy of polymyxin B-immobilized fiber hemoperfusion for patients with septic shock caused by Gram-negative bacillus infection. PLoS ONE 12:e0173633
pubmed: 28358803
pmcid: 5373513
doi: 10.1371/journal.pone.0173633
Chang T et al (2017) Effects of Polymyxin B Hemoperfusion on Mortality in Patients With Severe Sepsis and Septic Shock: A Systemic Review, Meta-Analysis Update, and Disease Severity Subgroup Meta-Analysis. Crit Care Med 45:e858–e864
pubmed: 28445237
pmcid: 5515642
doi: 10.1097/CCM.0000000000002362
Dellinger RP et al (2018) Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial. JAMA 320:1455–1463
pubmed: 30304428
pmcid: 6233793
doi: 10.1001/jama.2018.14618
Klein DJ et al (2018) Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med 44:2205–2212
pubmed: 30470853
pmcid: 6280819
doi: 10.1007/s00134-018-5463-7
Hayakawa M et al (2018) Nationwide registry of sepsis patients in Japan focused on disseminated intravascular coagulation 2011–2013. Sci Data 5:180243
pubmed: 30531950
pmcid: 6289115
doi: 10.1038/sdata.2018.243
Osawa I et al (2023) Targeted therapy using polymyxin B hemadsorption in patients with sepsis: a post-hoc analysis of the JSEPTIC-DIC study and the EUPHRATES trial. Crit Care Lond Engl 27:245
doi: 10.1186/s13054-023-04533-3
Fujii T et al (2018) Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 44:167–178
pubmed: 29204670
doi: 10.1007/s00134-017-5004-9
Formica M et al (2003) Hemodynamic response to coupled plasmafiltration-adsorption in human septic shock. Intensive Care Med 29:703–708
pubmed: 12665998
doi: 10.1007/s00134-003-1724-0
Livigni S et al (2014) Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial. BMJ Open 4:e003536
pubmed: 24401721
pmcid: 3902195
doi: 10.1136/bmjopen-2013-003536
Berlot G et al (2014) Effects of the volume of processed plasma on the outcome, arterial pressure and blood procalcitonin levels in patients with severe sepsis and septic shock treated with coupled plasma filtration and adsorption. Blood Purif 37:146–151
pubmed: 24777037
doi: 10.1159/000360268
Berlot G et al (2018) Influence of Timing of Initiation and Volume of Processed Plasma on the Outcome of Septic Shock Patients Treated with Coupled Plasma Filtration and Adsorption. Blood Purif 46:274–278
pubmed: 29969757
doi: 10.1159/000490611
Garbero E et al (2021) High dose coupled plasma filtration and adsorption in septic shock patients. Results of the COMPACT-2: a multicentre, adaptive, randomised clinical trial. Intensive Care Med 47(11):1303–1311
pubmed: 34601619
doi: 10.1007/s00134-021-06501-3
Shankar-Hari M, Spencer J, Sewell WA, Rowan KM, Singer M (2012) Bench-to-bedside review: Immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective. Crit Care Lond Engl 16:206
doi: 10.1186/cc10597
Ehrenstein MR, Notley CA (2010) The importance of natural IgM: scavenger, protector and regulator. Nat Rev Immunol 10:778–786
pubmed: 20948548
doi: 10.1038/nri2849
Bermejo-Martín JF et al (2014) Immunoglobulins IgG1, IgM and IgA: a synergistic team influencing survival in sepsis. J Intern Med 276:404–412
pubmed: 24815605
doi: 10.1111/joim.12265
Giamarellos-Bourboulis EJ et al (2013) Kinetics of circulating immunoglobulin M in sepsis: relationship with final outcome. Crit Care Lond Engl 17:R247
doi: 10.1186/cc13073
Kreymann KG, de Heer G, Nierhaus A, Kluge S (2007) Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 35:2677–2685
pubmed: 18074464
Soares MO et al (2012) An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis. Health Technol Assess Winch Engl 16:1–186
Alejandria MM, Lansang MAD, Dans LF, Iii JBM (2013) Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD001090.pub2
doi: 10.1002/14651858.CD001090.pub2
pubmed: 24043371
pmcid: 6516813
Busani S, Damiani E, Cavazzuti I, Donati A, Girardis M (2016) Intravenous immunoglobulin in septic shock: review of the mechanisms of action and meta-analysis of the clinical effectiveness. Minerva Anestesiol 82:559–572
pubmed: 26474267
Werdan K et al (2007) Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med 35:2693–2701
pubmed: 18074471
Singer M et al (2016) The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315:801–810
pubmed: 26903338
pmcid: 4968574
doi: 10.1001/jama.2016.0287
Darenberg J et al (2003) Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis Off Publ Infect Dis Soc Am 37:333–340
doi: 10.1086/376630
Linnér A, Darenberg J, Sjölin J, Henriques-Normark B, Norrby-Teglund A (2014) Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis Off Publ Infect Dis Soc Am 59:851–857
doi: 10.1093/cid/ciu449
Madsen MB et al (2017) Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): a randomised, blinded, placebo-controlled trial. Intensive Care Med 43:1585–1593
pubmed: 28421246
doi: 10.1007/s00134-017-4786-0
Kadri SS et al (2017) Impact of Intravenous Immunoglobulin on Survival in Necrotizing Fasciitis With Vasopressor-Dependent Shock: A Propensity Score-Matched Analysis From 130 US Hospitals. Clin Infect Dis Off Publ Infect Dis Soc Am 64:877–885
Welte T et al (2018) Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). Intensive Care Med 44:438–448
pubmed: 29632995
pmcid: 5924663
doi: 10.1007/s00134-018-5143-7
Tascini C et al (2018) Potential role of IgM-enriched immunoglobulin as adjuvant treatment for invasive meningococcal disease. Intensive Care Med 44:261–262
pubmed: 29124316
doi: 10.1007/s00134-017-4957-z
Rouget C et al (2017) Biological markers of injury-induced immunosuppression. Minerva Anestesiol 83:302–314
pubmed: 27314598
doi: 10.23736/S0375-9393.16.11268-4
Giamarellos-Bourboulis EJ et al (2016) Improving outcomes of severe infections by multidrug-resistant pathogens with polyclonal IgM-enriched immunoglobulins. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 22:499–506
Busani S et al (2017) The Role of Adjunctive Therapies in Septic Shock by Gram Negative MDR/XDR Infections. Can. J. Infect. Dis. Med. Microbiol. J. Can. Mal. Infect. Microbiol. Medicale 2017:2808203
Hentrich M et al (2006) IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial. Crit Care Med 34:1319–1325
pubmed: 16540956
doi: 10.1097/01.CCM.0000215452.84291.C6
Berlot G et al (2018) Effects of the timing of administration of IgM- and IgA-enriched intravenous polyclonal immunoglobulins on the outcome of septic shock patients. Ann Intensive Care 8:122
pubmed: 30535962
pmcid: 6288102
doi: 10.1186/s13613-018-0466-7
Nierhaus A et al (2003) Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med 29:646–651
pubmed: 12595977
doi: 10.1007/s00134-003-1666-6
Mhaskar R et al (2014) Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003039.pub2
doi: 10.1002/14651858.CD003039.pub2
pubmed: 25356786
pmcid: 10945354
Eichacker PQ et al (1994) Cardiopulmonary effects of granulocyte colony-stimulating factor in a canine model of bacterial sepsis. J Appl Physiol Bethesda Md 1985(77):2366–2373
Carr R, Modi N, Doré C (2003) G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane Database Syst. Rev 2003(3):CD003066
pubmed: 12917944
pmcid: 7016516
Bo L, Wang F, Zhu J, Li J, Deng X (2011) Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit Care Lond Engl 15:R58
doi: 10.1186/cc10031
Meisel C et al (2009) Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 180:640–648
pubmed: 19590022
doi: 10.1164/rccm.200903-0363OC
Paine R et al (2012) A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Crit Care Med 40:90–97
pubmed: 21926600
pmcid: 3242850
doi: 10.1097/CCM.0b013e31822d7bf0
Pinder EM et al (2018) Randomised controlled trial of GM-CSF in critically ill patients with impaired neutrophil phagocytosis. Thorax 73:918–925
pubmed: 30064991
doi: 10.1136/thoraxjnl-2017-211323
Sun J, Zhang X, Ma L, Yang Y, Li X (2023) Clinical study of rhGM-CSF for the treatment of pulmonary exogenous acute respiratory distress syndrome by modulating alveolar macrophage subtypes: A randomized controlled trial. Medicine (Baltimore) 102(19):e33770
pubmed: 37171348
doi: 10.1097/MD.0000000000033770
Prakash V, Arora V, Jindal A, Maiwall R, Sarin SK (2023) Combination of GM CSF and carbapenem is superior to carbapenem monotherapy in difficult-to-treat spontaneous bacterial peritonitis: A randomized controlled trial. Liver Int. 43(6):1298–1306
pubmed: 36748109
doi: 10.1111/liv.15534
Prucha M, Zazula R, Russwurm S (2017) Immunotherapy of Sepsis: Blind Alley or Call for Personalized Assessment? Arch Immunol Ther Exp (Warsz) 65:37–49
pubmed: 27554587
doi: 10.1007/s00005-016-0415-9
Francois B et al (2018) Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight 3(5):e98960
pubmed: 29515037
pmcid: 5922293
doi: 10.1172/jci.insight.98960
Unsinger J et al (2012) Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis. J Infect Dis 206:606–616
pubmed: 22693226
pmcid: 3491749
doi: 10.1093/infdis/jis383
Venet F et al (2012) IL-7 restores lymphocyte functions in septic patients. J Immunol Baltim Md 1950(189):5073–5081
Shindo Y, Unsinger J, Burnham C-A, Green JM, Hotchkiss RS (2015) Interleukin-7 and anti-programmed cell death 1 antibody have differing effects to reverse sepsis-induced immunosuppression. Shock Augusta Ga 43:334–343
pubmed: 25565644
doi: 10.1097/SHK.0000000000000317
Daix T et al (2023) Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial. Ann Intensive Care 13:17
pubmed: 36906875
pmcid: 10008152
doi: 10.1186/s13613-023-01109-w
Hotchkiss R et al (2018) 1504: Immune Checkpoint Inhibitors In Sepsis: A Phase 1B Trial Of Anti-PD-L1 (BMS-936559). Crit Care Med 46:736
doi: 10.1097/01.ccm.0000529506.43290.de
Patera AC et al (2016) Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1. J Leukoc Biol 100:1239–1254
pubmed: 27671246
pmcid: 5110001
doi: 10.1189/jlb.4HI0616-255R
Grimaldi D, Pradier O, Hotchkiss RS, Vincent J-L (2017) Nivolumab plus interferon-γ in the treatment of intractable mucormycosis. Lancet Infect Dis 17:18
pubmed: 27998559
doi: 10.1016/S1473-3099(16)30541-2
Valentine G, Thomas TA, Nguyen T, Lai Y-C (2014) Chronic granulomatous disease presenting as hemophagocytic lymphohistiocytosis: a case report. Pediatrics 134:e1727–1730
pubmed: 25422023
doi: 10.1542/peds.2014-2175
Payen D et al (2019) Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series BMC Infect Dis 19:931
pubmed: 31690258
doi: 10.1186/s12879-019-4526-x
Roquilly A et al (2023) Interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients: a phase 2, placebo-controlled randomized clinical trial. Intensive Care Med 49:530–544
pubmed: 37072597
pmcid: 10112824
doi: 10.1007/s00134-023-07065-0